Compound Detail
CHEMBL2023898
DACLATASVIR 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C
Basic Information
| ChEMBL ID | CHEMBL2023898 |
| Name | DACLATASVIR |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | FKRSSPOQAMALKA-CUPIEXAXSA-N |
| Therapeutic | ✓ Yes |
8
Targets
118
Activities
2
Assay Types
30
PK Parameters
20
Publications
5
Known Names
8
Indications
Molecular Properties
738.9
MW (Da)
6.22
ALogP
8
HBA
4
HBD
174.6
PSA (Ų)
0.14
QED
2
Ro5 Violations
11
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2014 |
| Availability | Discontinued |
| Chirality | Single Enantiomer |
Indications
Virus Diseases Hepatitis C Hepatitis C, Chronic Severe Acute Respiratory Syndrome Severe Acute Respiratory Syndrome Hepatitis B, Chronic Infections Renal Insufficiency, Chronic
ATC Classification
J05AP07
daclatasvir
Level 1: ANTIINFECTIVES FOR SYSTEMIC USE
Level 2: ANTIVIRALS FOR SYSTEMIC USE
Activity Summary
EC50 108 meas. best 11.0
IC50 10 meas. best 10.64
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Hepatitis C virus CHEMBL379 | EC50 | 11.0 | 9.712 | 0.0 | 66 |
| Nonstructural protein 5A CHEMBL3307224 | IC50 | 10.64 | 10.64 | 0.0 | 1 |
| Unchecked CHEMBL612545 | EC50 | 10.64 | 8.0775 | 0.0 | 4 |
| Hepatitis C virus CHEMBL379 | IC50 | 10.51 | 10.51 | 0.0 | 1 |
| Nonstructural protein 5A CHEMBL3307224 | EC50 | 10.49 | 9.2036 | 0.0 | 14 |
| SARS-CoV-2 CHEMBL4303835 | EC50 | 5.96 | 5.96 | 1100.0 | 1 |
| Cytochrome P450 3A4 CHEMBL340 | IC50 | 5.14 | 5.14 | 7200.0 | 3 |
| Bovine viral diarrhea virus 1 CHEMBL612571 | EC50 | 5.05 | 5.05 | 9000.0 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 4.54 | 4.54 | 29200.0 | 1 |
| Cytochrome P450 2C9 CHEMBL3397 | IC50 | 4.22 | 4.22 | 59500.0 | 3 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 1426.06 | ng.hr.mL-1 | Macaca mulatta |
| AUC | 8127.79 | ng.hr.mL-1 | Canis lupus familiaris |
| AUC | 3546.67 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1611.52 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 3546.67 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 8127.79 | ng.hr.mL-1 | Canis lupus familiaris |
| AUC | 1426.06 | ng.hr.mL-1 | Macaca fascicularis |
| AUC | 3320.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 3210.0 | ng.hr.mL-1 | Rattus norvegicus |
| Cmax | 728.0 | nM | Rattus norvegicus |
| Cmax | 500.0 | nM | Macaca mulatta |
| Cmax | 655.04 | nM | Rattus norvegicus |
| F | 38.0 | % | Macaca mulatta |
| F | 108.0 | % | Canis lupus familiaris |
| F | 50.0 | % | Rattus norvegicus |
| F | 50.0 | % | Rattus norvegicus |
| F | 108.0 | % | Canis lupus familiaris |
| F | 38.0 | % | Macaca fascicularis |
| F | 50.0 | % | Rattus norvegicus |
| F | 58.5 | % | Canis lupus familiaris |
| F | 38.0 | % | Macaca mulatta |
| F | 50.0 | % | Rattus norvegicus |
| F | 67.0 | % | Homo sapiens |
| F | 67.0 | % | Homo sapiens |
| MRT | 3.43 | hr | Rattus norvegicus |
| T1/2 | 0.9383 | hr | Homo sapiens |
| T1/2 | 1.5 | hr | Rattus norvegicus |
| T1/2 | 3.0 | hr | Macaca mulatta |
| T1/2 | 1.66 | hr | Rattus norvegicus |
| T1/2 | 12.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine